US Transdermal Patch Market Outlook 2020
Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.
The last two decades have witnessed rapid growth in multiple innovations and commercialization of new medicinal agents and drug delivery mechanism. These innovations in drug delivery systems have not only enabled the successful implementation of many of these novel pharmaceuticals products such as transdermal patches, but have also permitted the development of new medical treatments with existing drugs. The need of more innovation in field of transdermal drug delivery system is still huge and will remain so in the upcoming years of the medicinal world.
If taken a look at the medicinal markets of the world, indeed they are now replete with medications designed to ease and cure the symptoms associated with thousands of conditions. Traditional medication delivery methods, such as pills, capsules, liquids, powders, and intravenous needles, are often inefficient or invasive and can lead to undesirable side effects.
Amongst the newer methodologies for administration of medicines is the use of transdermal approaches, including gels and patches for the treatment of many of the more common ailments. The creation of transdermal delivery systems has been one of the most important innovations, offering a number of advantages over the oral route.
Transdermal patches comprise a method of delivering medication through the skin in a non-invasive manner. During transdermal drug delivery, a patch is simply applied on the epidermal layer of a patient’s skin. The patch is modulated to contain the medication prescribed to the patient and is designed in such a way that the medication permeates the skin in a controlled fashion thus attaining more steady levels of the drug in the body.
Transdermal patches presently donning the market are formulated in accordance with requirement of the medicinal therapy. They can be worn for as low as 8 hours to as long as 7 days depending on the therapeutic indication. These patches are secured with adhesives, which are designed to adhere comfortably to the skin which in turn allows a patient to use the patches for as long as is indicated by his or her physician. Transdermal drug delivery provides excellent control of the rate of delivery directly into the bloodstream. It also offers a predictable pharmacokinetic profile and constant drug levels over extended periods of time without the extreme peak/trough fluctuations inherent in oral administration with the inherent power of discontinuation of therapy immediately by simply removing the patch.
The market for transdermal products has skyrocketed since its innovation and is likely to continue for the foreseeable future. An increasing number of Transdermal drug delivery (TDD) products continue to deliver real therapeutic benefit to patients around the world. The FDA approved a total of 32 transdermal products over the past 20 years, the majority of which use passive transport that allows the drug to be continually absorbed into the skin via natural processes.
Technologies behind transdermal patches are improving continuously and have been introduced for different indication in US. They have been introduced for new indications for which no transdermal product was available allowing them to occupy major market shares. Increase in demand for better therapeutics at affordable prices is expected to be the main factor behind their growth in US market. Improved material science, advanced manufacturing capabilities and high acceptance rates will further propel growth in this segment. However, some immediate issues like lesser coverage of indications have yet to be overcome in coming years. Another issue is technology related, which has definitely improved, but needs to be improved in order to come forth with diseases like HIV infection. Overall, transdermal patch market in US is expected to grow continuously reflecting optimistic future.
“US Transdermal Patch Market Outlook 2020” Report Highlights:
The last two decades have witnessed rapid growth in multiple innovations and commercialization of new medicinal agents and drug delivery mechanism. These innovations in drug delivery systems have not only enabled the successful implementation of many of these novel pharmaceuticals products such as transdermal patches, but have also permitted the development of new medical treatments with existing drugs. The need of more innovation in field of transdermal drug delivery system is still huge and will remain so in the upcoming years of the medicinal world.
If taken a look at the medicinal markets of the world, indeed they are now replete with medications designed to ease and cure the symptoms associated with thousands of conditions. Traditional medication delivery methods, such as pills, capsules, liquids, powders, and intravenous needles, are often inefficient or invasive and can lead to undesirable side effects.
Amongst the newer methodologies for administration of medicines is the use of transdermal approaches, including gels and patches for the treatment of many of the more common ailments. The creation of transdermal delivery systems has been one of the most important innovations, offering a number of advantages over the oral route.
Transdermal patches comprise a method of delivering medication through the skin in a non-invasive manner. During transdermal drug delivery, a patch is simply applied on the epidermal layer of a patient’s skin. The patch is modulated to contain the medication prescribed to the patient and is designed in such a way that the medication permeates the skin in a controlled fashion thus attaining more steady levels of the drug in the body.
Transdermal patches presently donning the market are formulated in accordance with requirement of the medicinal therapy. They can be worn for as low as 8 hours to as long as 7 days depending on the therapeutic indication. These patches are secured with adhesives, which are designed to adhere comfortably to the skin which in turn allows a patient to use the patches for as long as is indicated by his or her physician. Transdermal drug delivery provides excellent control of the rate of delivery directly into the bloodstream. It also offers a predictable pharmacokinetic profile and constant drug levels over extended periods of time without the extreme peak/trough fluctuations inherent in oral administration with the inherent power of discontinuation of therapy immediately by simply removing the patch.
The market for transdermal products has skyrocketed since its innovation and is likely to continue for the foreseeable future. An increasing number of Transdermal drug delivery (TDD) products continue to deliver real therapeutic benefit to patients around the world. The FDA approved a total of 32 transdermal products over the past 20 years, the majority of which use passive transport that allows the drug to be continually absorbed into the skin via natural processes.
Technologies behind transdermal patches are improving continuously and have been introduced for different indication in US. They have been introduced for new indications for which no transdermal product was available allowing them to occupy major market shares. Increase in demand for better therapeutics at affordable prices is expected to be the main factor behind their growth in US market. Improved material science, advanced manufacturing capabilities and high acceptance rates will further propel growth in this segment. However, some immediate issues like lesser coverage of indications have yet to be overcome in coming years. Another issue is technology related, which has definitely improved, but needs to be improved in order to come forth with diseases like HIV infection. Overall, transdermal patch market in US is expected to grow continuously reflecting optimistic future.
“US Transdermal Patch Market Outlook 2020” Report Highlights:
- US Transdermal Patch Market Overview
- Generic & Branded Transdermal Patches
- US Transdermal Patch Market: Value Chain Analysis
- US Transdermal Patch Contract Manufacturing Organization
- US Transdermal Patch Clinical Pipeline Insight by Company, Indication & Phase
- US Transdermal Patch Clinical Pipeline: 55 Patches
- Majority Patches in Preclinical Phase: 23 Patches
- Marketed Transdermal Patch Clinical Insight by Company & Indication
- Marketed Transdermal Patches in US: 32 Patches
1. INTRODUCTION TO TRANSDERMAL PATCH
2. CLASSIFICATION OF TRANSDERMAL PATCHES
2.1 Single/ Multiple-Layer Drug-in-Adhesive
2.2 Reservoir Transdermal Patches
2.3 Matrix Based Transdermal Patches
2.4 Vapor Patch
2.5 Active and Passive Patch
3. WHY THERE EXIST NEED FOR TRANSDERMAL PATCHES?
4. MECHANISM OF TRANSDERMAL PATCH DRUG DELIVERY
4.1 Properties of Transdermal Therapeutics
4.2 Components of Transdermal Patch
4.3 Mechanism of Motion Sickness, Nicotine & Female Contraceptive Transdermal Patch
5. TRANSDERMAL PATCH V/S TRADITIONAL DRUG DELIVERY METHODS
6. US TRANSDERMAL PATCH MARKET OVERVIEW
6.1 Current Market Scenario
6.2 US Transdermal Patch Clinical Pipeline Overview
7. GENERIC & BRANDED TRANSDERMAL PATCHES
8. VALUE CHAIN ANALYSIS FOR TRANSDERMAL PATCH MARKET
8.1 Research & Development
8.2 Manufacturing
8.3 Marketing & Distribution
8.4 Price to End User
9. US TRANSDERMAL PATCH CONTRACT MANUFACTURING ORGANIZATION (CMO)
10. US TRANSDERMAL PATCH MARKET OPPORTUNITY ASSESSMENT
10.1 Parkinson’s Disease
10.2 Alzheimer's Disease
10.3 Female Contraceptive
10.4 Nicotine Replacement Therapy
10.5 Insulin
10.6 Vaccine
11. US TRANSDERMAL PATCH MARKET DYNAMICS
11.1 Favorable Market Parameters
11.2 Commercialization Challenges
12. US TRANSDERMAL PATCH MARKET FUTURE PROSPECTS
13. US TRANSDERMAL PATCH CLINICAL PIPELINE BY COMPANY, INDICATION & PHASE
13.1 Research
13.2 Preclinical
13.3 Phase-I
13.4 Phase-I/II
13.5 Phase-II
13.6 Phase-II/III
13.7 Phase-III
13.8 Preregistration
13.9 Registered
14. MARKETED TRANSDERMAL PATCH CLINICAL INSIGHT BY COMPANY & INDICATION
15. DISCONTINUED & NO DEVELOPMENT REPORTED IN US TRANSDERMAL PATCH CLINICAL PIPELINE
15.1 No Development Reported
15.2 Discontinued
15.3 Marketed Withdrawal
16. COMPETITIVE LANDSCAPE
16.1 3M Pharmaceuticals
16.2 Acrux
16.3 Agile Therapeutics
16.4 Allergan
16.5 ANI Pharmaceuticals
16.6 Antares Pharma
16.7 Bayer HealthCare Pharmaceuticals
16.8 Corium International
16.9 Chase Pharmaceuticals
16.10 DURECT Corporation
16.11 Endo Pharmaceuticals
16.12 Fempharm
16.13 Hisamitsu Pharmaceutical
16.14 Immune Pharmaceuticals
16.15 Imprimis Pharmaceuticals
16.16 Ipsen Bioscience
16.17 Johnson & Johnson
16.18 LaSalle Laboratories
16.19 Lavipharm-increase
16.20 MINRAD International
16.21 NeurogesX
16.22 Noven Pharmaceuticals
16.23 NuPathe
16.24 Nuvo Research
16.25 Novartis
16.26 Pain Therapeutics
16.27 ProStrakan
16.28 Purdue Pharma
16.29 Sanofi
16.30 Scilex Pharmaceuticals
16.31 Senju Pharmaceutical
16.32 Somerset Pharmaceuticals
16.33 Teikoku Seiyaku
16.34 Therapeutic Discovery Corporation
16.35 Transdermal Delivery Solutions Corp
16.36 UCB
16.37 Xel Pharmaceuticals
16.38 Zosano Pharma
2. CLASSIFICATION OF TRANSDERMAL PATCHES
2.1 Single/ Multiple-Layer Drug-in-Adhesive
2.2 Reservoir Transdermal Patches
2.3 Matrix Based Transdermal Patches
2.4 Vapor Patch
2.5 Active and Passive Patch
3. WHY THERE EXIST NEED FOR TRANSDERMAL PATCHES?
4. MECHANISM OF TRANSDERMAL PATCH DRUG DELIVERY
4.1 Properties of Transdermal Therapeutics
4.2 Components of Transdermal Patch
4.3 Mechanism of Motion Sickness, Nicotine & Female Contraceptive Transdermal Patch
5. TRANSDERMAL PATCH V/S TRADITIONAL DRUG DELIVERY METHODS
6. US TRANSDERMAL PATCH MARKET OVERVIEW
6.1 Current Market Scenario
6.2 US Transdermal Patch Clinical Pipeline Overview
7. GENERIC & BRANDED TRANSDERMAL PATCHES
8. VALUE CHAIN ANALYSIS FOR TRANSDERMAL PATCH MARKET
8.1 Research & Development
8.2 Manufacturing
8.3 Marketing & Distribution
8.4 Price to End User
9. US TRANSDERMAL PATCH CONTRACT MANUFACTURING ORGANIZATION (CMO)
10. US TRANSDERMAL PATCH MARKET OPPORTUNITY ASSESSMENT
10.1 Parkinson’s Disease
10.2 Alzheimer's Disease
10.3 Female Contraceptive
10.4 Nicotine Replacement Therapy
10.5 Insulin
10.6 Vaccine
11. US TRANSDERMAL PATCH MARKET DYNAMICS
11.1 Favorable Market Parameters
11.2 Commercialization Challenges
12. US TRANSDERMAL PATCH MARKET FUTURE PROSPECTS
13. US TRANSDERMAL PATCH CLINICAL PIPELINE BY COMPANY, INDICATION & PHASE
13.1 Research
13.2 Preclinical
13.3 Phase-I
13.4 Phase-I/II
13.5 Phase-II
13.6 Phase-II/III
13.7 Phase-III
13.8 Preregistration
13.9 Registered
14. MARKETED TRANSDERMAL PATCH CLINICAL INSIGHT BY COMPANY & INDICATION
15. DISCONTINUED & NO DEVELOPMENT REPORTED IN US TRANSDERMAL PATCH CLINICAL PIPELINE
15.1 No Development Reported
15.2 Discontinued
15.3 Marketed Withdrawal
16. COMPETITIVE LANDSCAPE
16.1 3M Pharmaceuticals
16.2 Acrux
16.3 Agile Therapeutics
16.4 Allergan
16.5 ANI Pharmaceuticals
16.6 Antares Pharma
16.7 Bayer HealthCare Pharmaceuticals
16.8 Corium International
16.9 Chase Pharmaceuticals
16.10 DURECT Corporation
16.11 Endo Pharmaceuticals
16.12 Fempharm
16.13 Hisamitsu Pharmaceutical
16.14 Immune Pharmaceuticals
16.15 Imprimis Pharmaceuticals
16.16 Ipsen Bioscience
16.17 Johnson & Johnson
16.18 LaSalle Laboratories
16.19 Lavipharm-increase
16.20 MINRAD International
16.21 NeurogesX
16.22 Noven Pharmaceuticals
16.23 NuPathe
16.24 Nuvo Research
16.25 Novartis
16.26 Pain Therapeutics
16.27 ProStrakan
16.28 Purdue Pharma
16.29 Sanofi
16.30 Scilex Pharmaceuticals
16.31 Senju Pharmaceutical
16.32 Somerset Pharmaceuticals
16.33 Teikoku Seiyaku
16.34 Therapeutic Discovery Corporation
16.35 Transdermal Delivery Solutions Corp
16.36 UCB
16.37 Xel Pharmaceuticals
16.38 Zosano Pharma
LIST OF FIGURES
Figure 1-1: Steps Involved in Transdermal Permeation
Figure 1-2: Ideal Properties of Transdermal Patch
Figure 2-1: Types of Commercially Available Transdermal Patch
Figure 4-1: Properties of Transdermal Therapeutics
Figure 4-2: Components of Transdermal Patch
Figure 4-3: Types of Permeation Enhancers
Figure 4-4: Schematic Representation of Iontophoresis
Figure 4-5: Mechanism of Scopolamine Transdermal Patch
Figure 4-6: Mechanism of Nicotine Transdermal Patch
Figure 4-7: Mechanism of Female Contraceptive Transdermal Patch
Figure 5-1: Issues with Traditional Drug Delivery Methods
Figure 5-2: Advantages of Transdermal Patch
Figure 5-3: Consistent Drug Supply by Transdermal Patch
Figure 6-1: Advantages of Transdermal Patches
Figure 6-2: Disadvantages of Transdermal Patches
Figure 6-3: US - Major Reasons Behind Growth of Transdermal Patches
Figure 6-4: US - Estimated Prescription Drug Spending (USD Billion), 2015-2020
Figure 6-5: US- Transdermal Drug Delivery System Market (US$ Billion), 2015-2020
Figure 6-6: US - Estimated Prescription Transdermal Patch Market by Volume (%), 2015 & 2020
Figure 6-7: US - Estimated Market Size of Prescription vs. Over-The-Counter Transdermal Patches (US$ Billion), 2015
Figure 6-8: US - Estimated Market Size of Prescription vs. Over-The-Counter Transdermal Patches (US$ Billion), 2020
Figure 6-9: US Transdermal Patch Pipeline by Phase (%), 2016
Figure 6-10: US Transdermal Patch Pipeline by Phase (Numbers), 2016
Figure 6-11: US Transdermal Patch Pipeline by Phase (%), 2016
Figure 6-12: US Transdermal Patch Pipeline by Phase (Numbers), 2016
Figure 7-1: Requirement in Generic Transdermal Patches
Figure 7-2: Reservations for Generic Transdermal Patches
Figure 7-3: US - Estimated Cost Comparison of Branded vs. Generic Contraceptive Patch
Figure 7-4: US - Estimated Cost Comparison of Cigarettes, Generic & Branded Nicotine Patches
Figure 8-1: Basic Features of Transdermal Patch Value Chain
Figure 8-2: Steps Involved in Transdermal Patch Manufacturing
Figure 9-1: Stages of Transdermal Patch Development
Figure 9-2: Advantages of Using Contract Manufacturing Organization for Transdermal Drug Delivery System
Figure 9-3: Requirements from Contract Manufacturing Organization for Transdermal Drug Delivery System
Figure 10-1: Potential Market Segments of Transdermal Drug Delivery Systems
Figure 10-2: US - Susceptibility of Parkinson Disease among Males and Females
Figure 10-3: US - Estimated Increase in Parkinson’s Disease Incidences
Figure 10-4: US - Estimated Financial Impact of Parkinson’s Disease on Economy (US$ Billion)
Figure 10-5: US - Parkinson’s Disease Incidences, 2015-2020
Figure 10-6: US - Estimated Sales of Neupro Patch, 2104-2020
Figure 10-7: US - Estimated Worldwide Sales of Neupro, 2014 & 2015
Figure 10-8: US - Male & Female Suffering from Alzheimer’s Disease (Million), 2015
Figure 10-9: US - Shares of Male & Female Suffering from Alzheimer’s Disease (%), 2015
Figure 10-10: US - Percentage of Elderly People Suffering from Alzheimer’s Disease, 2015
Figure 10-11: US - Estimated Increase in Alzheimer’s Incidences, 2015, 2025 & 2050
Figure 10-12: US - Estimated Incidences of Alzheimer’s Disease, 2015-2020
Figure 10-13: US - Exelon Patch Sales for Alzheimer's Disease, 2013 & 2014
Figure 10-14: Requirements of Female Contraceptive Transdermal Drug Delivery Systems
Figure 10-15: Benefits of Female Contraceptive Transdermal Drug Delivery System
Figure 10-16: US - Expected Revenues Generated by Xulane Patch (US$ Million), 2015-2020
Figure 10-17: US - Decrease in Number of Smokers due to Nicotine Patch, 2005 & 2013
Figure 10-18: Factors Responsible for Increased Consumption of Nicotine Patches
Figure 10-19: Rank of US among Different Diabetes Prone Countries
Figure 10-20: US - Estimated Increase in Diabetes Incidences, 2015-2020
Figure 10-21: Benefits of Insulin Transdermal Patch
Figure 10-22: Drawback of Insulin Transdermal Patch
Figure 10-23: Benefits of Vaccine Transdermal Patch
Figure 10-24: Drawbacks of Vaccine Transdermal Patch
Figure 10-25: US - Estimated HIV Incidences, 2015-2020
Figure 11-1: Transdermal Patch Market Favorable Factors
Figure 11-2: Transdermal Patch Market Commercialization Challenges
Figure 16-1: Acrux Clinical Pipeline
Figure 16-2: Agile Therapeutics Clinical Pipeline
Figure 16-3: Antares Pharma Clinical Pipeline
Figure 16-4: Corium International Clinical Pipeline
Figure 16-5: Durect Corporation Clinical Pipeline
Figure 16-6: Endo Pharmaceuticals Clinical Pipeline
Figure 16-7: Immune Pharmaceuticals Clinical Pipeline
Figure 16-8: Novartis Clinical Pipeline
Figure 16-9: Senju Pharmaceuticals Clinical Pipeline
Figure 16-10: Xel Pharamaceuticals Clinical Pipeline
Figure 16-11: Zosano Pharma Clinical Pipeline
Figure 1-1: Steps Involved in Transdermal Permeation
Figure 1-2: Ideal Properties of Transdermal Patch
Figure 2-1: Types of Commercially Available Transdermal Patch
Figure 4-1: Properties of Transdermal Therapeutics
Figure 4-2: Components of Transdermal Patch
Figure 4-3: Types of Permeation Enhancers
Figure 4-4: Schematic Representation of Iontophoresis
Figure 4-5: Mechanism of Scopolamine Transdermal Patch
Figure 4-6: Mechanism of Nicotine Transdermal Patch
Figure 4-7: Mechanism of Female Contraceptive Transdermal Patch
Figure 5-1: Issues with Traditional Drug Delivery Methods
Figure 5-2: Advantages of Transdermal Patch
Figure 5-3: Consistent Drug Supply by Transdermal Patch
Figure 6-1: Advantages of Transdermal Patches
Figure 6-2: Disadvantages of Transdermal Patches
Figure 6-3: US - Major Reasons Behind Growth of Transdermal Patches
Figure 6-4: US - Estimated Prescription Drug Spending (USD Billion), 2015-2020
Figure 6-5: US- Transdermal Drug Delivery System Market (US$ Billion), 2015-2020
Figure 6-6: US - Estimated Prescription Transdermal Patch Market by Volume (%), 2015 & 2020
Figure 6-7: US - Estimated Market Size of Prescription vs. Over-The-Counter Transdermal Patches (US$ Billion), 2015
Figure 6-8: US - Estimated Market Size of Prescription vs. Over-The-Counter Transdermal Patches (US$ Billion), 2020
Figure 6-9: US Transdermal Patch Pipeline by Phase (%), 2016
Figure 6-10: US Transdermal Patch Pipeline by Phase (Numbers), 2016
Figure 6-11: US Transdermal Patch Pipeline by Phase (%), 2016
Figure 6-12: US Transdermal Patch Pipeline by Phase (Numbers), 2016
Figure 7-1: Requirement in Generic Transdermal Patches
Figure 7-2: Reservations for Generic Transdermal Patches
Figure 7-3: US - Estimated Cost Comparison of Branded vs. Generic Contraceptive Patch
Figure 7-4: US - Estimated Cost Comparison of Cigarettes, Generic & Branded Nicotine Patches
Figure 8-1: Basic Features of Transdermal Patch Value Chain
Figure 8-2: Steps Involved in Transdermal Patch Manufacturing
Figure 9-1: Stages of Transdermal Patch Development
Figure 9-2: Advantages of Using Contract Manufacturing Organization for Transdermal Drug Delivery System
Figure 9-3: Requirements from Contract Manufacturing Organization for Transdermal Drug Delivery System
Figure 10-1: Potential Market Segments of Transdermal Drug Delivery Systems
Figure 10-2: US - Susceptibility of Parkinson Disease among Males and Females
Figure 10-3: US - Estimated Increase in Parkinson’s Disease Incidences
Figure 10-4: US - Estimated Financial Impact of Parkinson’s Disease on Economy (US$ Billion)
Figure 10-5: US - Parkinson’s Disease Incidences, 2015-2020
Figure 10-6: US - Estimated Sales of Neupro Patch, 2104-2020
Figure 10-7: US - Estimated Worldwide Sales of Neupro, 2014 & 2015
Figure 10-8: US - Male & Female Suffering from Alzheimer’s Disease (Million), 2015
Figure 10-9: US - Shares of Male & Female Suffering from Alzheimer’s Disease (%), 2015
Figure 10-10: US - Percentage of Elderly People Suffering from Alzheimer’s Disease, 2015
Figure 10-11: US - Estimated Increase in Alzheimer’s Incidences, 2015, 2025 & 2050
Figure 10-12: US - Estimated Incidences of Alzheimer’s Disease, 2015-2020
Figure 10-13: US - Exelon Patch Sales for Alzheimer's Disease, 2013 & 2014
Figure 10-14: Requirements of Female Contraceptive Transdermal Drug Delivery Systems
Figure 10-15: Benefits of Female Contraceptive Transdermal Drug Delivery System
Figure 10-16: US - Expected Revenues Generated by Xulane Patch (US$ Million), 2015-2020
Figure 10-17: US - Decrease in Number of Smokers due to Nicotine Patch, 2005 & 2013
Figure 10-18: Factors Responsible for Increased Consumption of Nicotine Patches
Figure 10-19: Rank of US among Different Diabetes Prone Countries
Figure 10-20: US - Estimated Increase in Diabetes Incidences, 2015-2020
Figure 10-21: Benefits of Insulin Transdermal Patch
Figure 10-22: Drawback of Insulin Transdermal Patch
Figure 10-23: Benefits of Vaccine Transdermal Patch
Figure 10-24: Drawbacks of Vaccine Transdermal Patch
Figure 10-25: US - Estimated HIV Incidences, 2015-2020
Figure 11-1: Transdermal Patch Market Favorable Factors
Figure 11-2: Transdermal Patch Market Commercialization Challenges
Figure 16-1: Acrux Clinical Pipeline
Figure 16-2: Agile Therapeutics Clinical Pipeline
Figure 16-3: Antares Pharma Clinical Pipeline
Figure 16-4: Corium International Clinical Pipeline
Figure 16-5: Durect Corporation Clinical Pipeline
Figure 16-6: Endo Pharmaceuticals Clinical Pipeline
Figure 16-7: Immune Pharmaceuticals Clinical Pipeline
Figure 16-8: Novartis Clinical Pipeline
Figure 16-9: Senju Pharmaceuticals Clinical Pipeline
Figure 16-10: Xel Pharamaceuticals Clinical Pipeline
Figure 16-11: Zosano Pharma Clinical Pipeline
LIST OF TABLES
Table 4-1: Transdermal Patches for Various Disease Indications
Table 6-1: Features Required in Transdermal Patches
Table 6-2: US - Different Transdermal Drug Delivery Systems Available in Market
Table 7-1: Similarities & Difference Between Generic & Branded Transdermal Patches
Table 7-2: US - Some Generic Transdermal Patches Available in Market
Table 8-1: Breakdown of Transdermal Patch Value Chain Analysis
Table 10-1: US - Estimated Adoption Rates for Parkinson's Disease Transdermal Patches, 2015-2020
Table 10-2: Description of Neupro Patch for Parkinson’s Disease
Table 10-3: US - Estimated Adoption Rates for Transdermal Drug Delivery Systems for Alzheimer's Disease, 2015-2020
Table 10-4: Transdermal Patches for Alzheimer’s Disease
Table 10-5: Description of Ortho Evra Contraceptive Patch
Table 10-6: Difference Between Generic & Branded Transdermal Contraceptive Products
Table 10-7: US-Estimated Adoption Rates for Transdermal Drug Delivery Systems for Diabetes Mellitus, 2015-2020
Table 10-8: US-Estimated Adoption rates for Transdermal Drug Delivery Systems for HIV, 2015-2020
Table 16-1: Pain Therapeutics Clinical Pipeline
COMPANIES MENTIONED
3M Pharmaceuticals
Acrux
Agile Therapeutics
Allergan
ANI Pharmaceuticals
Antares Pharma
Bayer HealthCare Pharmaceuticals
Corium International
Chase Pharmaceuticals
DURECT Corporation
Endo Pharmaceuticals
Fempharm
Hisamitsu Pharmaceutical
Immune Pharmaceuticals
Imprimis Pharmaceuticals
Ipsen Bioscience
Johnson & Johnson
LaSalle Laboratories
Lavipharm-increase
MINRAD International
NeurogesX
Noven Pharmaceuticals
NuPathe
Nuvo Research
Novartis
Pain Therapeutics
ProStrakan
Purdue Pharma
Sanofi
Scilex Pharmaceuticals
Senju Pharmaceutical
Somerset Pharmaceuticals
Teikoku Seiyaku
Therapeutic Discovery Corporation
Transdermal Delivery Solutions
UCB
Xel Pharmaceuticals
Zosano Pharma
Table 4-1: Transdermal Patches for Various Disease Indications
Table 6-1: Features Required in Transdermal Patches
Table 6-2: US - Different Transdermal Drug Delivery Systems Available in Market
Table 7-1: Similarities & Difference Between Generic & Branded Transdermal Patches
Table 7-2: US - Some Generic Transdermal Patches Available in Market
Table 8-1: Breakdown of Transdermal Patch Value Chain Analysis
Table 10-1: US - Estimated Adoption Rates for Parkinson's Disease Transdermal Patches, 2015-2020
Table 10-2: Description of Neupro Patch for Parkinson’s Disease
Table 10-3: US - Estimated Adoption Rates for Transdermal Drug Delivery Systems for Alzheimer's Disease, 2015-2020
Table 10-4: Transdermal Patches for Alzheimer’s Disease
Table 10-5: Description of Ortho Evra Contraceptive Patch
Table 10-6: Difference Between Generic & Branded Transdermal Contraceptive Products
Table 10-7: US-Estimated Adoption Rates for Transdermal Drug Delivery Systems for Diabetes Mellitus, 2015-2020
Table 10-8: US-Estimated Adoption rates for Transdermal Drug Delivery Systems for HIV, 2015-2020
Table 16-1: Pain Therapeutics Clinical Pipeline
COMPANIES MENTIONED
3M Pharmaceuticals
Acrux
Agile Therapeutics
Allergan
ANI Pharmaceuticals
Antares Pharma
Bayer HealthCare Pharmaceuticals
Corium International
Chase Pharmaceuticals
DURECT Corporation
Endo Pharmaceuticals
Fempharm
Hisamitsu Pharmaceutical
Immune Pharmaceuticals
Imprimis Pharmaceuticals
Ipsen Bioscience
Johnson & Johnson
LaSalle Laboratories
Lavipharm-increase
MINRAD International
NeurogesX
Noven Pharmaceuticals
NuPathe
Nuvo Research
Novartis
Pain Therapeutics
ProStrakan
Purdue Pharma
Sanofi
Scilex Pharmaceuticals
Senju Pharmaceutical
Somerset Pharmaceuticals
Teikoku Seiyaku
Therapeutic Discovery Corporation
Transdermal Delivery Solutions
UCB
Xel Pharmaceuticals
Zosano Pharma
